Behavioral profile of adult zebrafish acutely exposed to a selective dopamine uptake inhibitor, GBR 12909. 2023

Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
Department of Neurobiology, Sirius University of Science and Technology, Sirius Federal Territory, Russia.

The dopamine transporter (DAT) is the main regulator of dopamine concentration in the extrasynaptic space. The pharmacological inhibition of the DAT results in a wide spectrum of behavioral manifestations, which have been identified so far in a limited number of species, mostly in rodents. Here, we used another well-recognized model organism, the zebrafish (Danio rerio), to explore the behavioral effects of GBR 12909, a highly-affine selective DAT blocker. We evaluated zebrafish locomotion, novelty-related exploration, spatial cognition, and social phenotypes in the novel tank, habituation and shoaling tests, following acute 20-min water immersion in GBR 12909. Our findings show hypolocomotion, anxiety-like state, and impaired spatial cognition in fish acutely treated with GBR 12909. This behavioral profile generally parallels that of the DAT knockout rodents and zebrafish, and it overlaps with behavioral effects of other DAT-inhibiting drugs of abuse, such as cocaine and D-amphetamine. Collectively, our data support the utility of zebrafish in translational studies on DAT targeting neuropharmacology and strongly implicate DAT aberration as an important mechanisms involved in neurological and psychiatric diseases.

UI MeSH Term Description Entries
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015027 Zebrafish An exotic species of the family CYPRINIDAE, originally from Asia, that has been introduced in North America. Zebrafish is a model organism for drug assay and cancer research. Brachydanio rerio,Danio rerio,B. rerio,D. rerio,Zebra Fish,Zebra Fishes,Zebra danio,Zebrafishes,D. rerios,Fishes, Zebra,Zebra danios,danio, Zebra
D050483 Dopamine Plasma Membrane Transport Proteins Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS. Dopamine Plasma Membrane Transporter Proteins,Neurotransmitter Transport Proteins, Dopamine-Specific,Neurotransmitter Transporters, Dopamine-Specific,DAT Dopamine Transporter,DAT Dopamine Transporter Proteins,Dopamine Carriers,Dopamine Transporter,Dopamine Transporter Proteins,Dopamine Uptake Complex,SLC6A3 Protein,Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 Protein,Carriers, Dopamine,Dopamine Transporter, DAT,Dopamine-Specific Neurotransmitter Transporters,Neurotransmitter Transport Proteins, Dopamine Specific,Neurotransmitter Transporters, Dopamine Specific,Protein, SLC6A3,Transporter Proteins, Dopamine,Transporter, DAT Dopamine,Transporter, Dopamine,Transporters, Dopamine-Specific Neurotransmitter
D018765 Dopamine Uptake Inhibitors Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. Dopamine Reuptake Inhibitors,Inhibitors, Dopamine Reuptake,Inhibitors, Dopamine Uptake,Reuptake Inhibitors, Dopamine,Uptake Inhibitors, Dopamine

Related Publications

Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
January 1994, Life sciences,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
August 1984, European journal of pharmacology,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
July 1991, Brain research bulletin,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
April 1991, Japanese journal of pharmacology,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
May 1994, Pharmacology, biochemistry, and behavior,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
August 1989, European journal of pharmacology,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
March 2007, Neuroscience,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
October 1990, International clinical psychopharmacology,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
January 2002, International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience,
Konstantin N Zabegalov, and Fabiano Costa, and Yuliya A Viktorova, and Gleb O Maslov, and Tatiana O Kolesnikova, and Elena V Gerasimova, and Vladimir P Grinevich, and Evgeny A Budygin, and Allan V Kalueff
January 1995, Life sciences,
Copied contents to your clipboard!